Last updated: June 3, 2026
Executive summary
Piflufolastat F-18 is an FDA-cleared PET imaging radiotracer for PSMA-positive prostate cancer (PSMA-targeted diagnostic). The near-term market is driven by (1) the cadence of PSMA-PET adoption in oncology workflows, (2) scan throughput constraints at cyclotron and radiopharmacy sites, and (3) insurer coverage and provider credentialing. Patent and regulatory exclusivity are expected to constrain direct competitive “identical tracer” entries, pushing future competition toward next-generation PSMA ligands and radiopharmaceuticals with differentiated targeting, improved kinetics, or alternative synthesis/manufacturing economics rather than immediate generic substitution.
What is Piflufolastat F-18 and what clinical evidence supports its use?
Piflufolastat F-18 is a PSMA-targeted positron emission tomography (PET) radiotracer used for imaging PSMA-positive prostate cancer. Commercial adoption has tracked clinical guideline uptake for PSMA-PET and expanding “precision staging” and “restaging” use in biochemical recurrence and other decision points in disease management.
What patient populations have been studied most
Across pivotal and follow-on studies, the clinical evidence base is concentrated in:
- Biochemical recurrence settings (initial restaging and detection at low PSA values)
- Staging and restaging workflows in recurrent or progressive prostate cancer
- Lesion detectability and concordance endpoints versus reference standards (histopathology, standard-of-care imaging, and composite readouts)
What endpoints drive differentiation
Commercial uptake responds to measurable readouts rather than qualitative clinician impressions:
- Lesion detection rates by anatomic site and PSA strata
- Sensitivity/specificity or concordance metrics using reference standards
- Imaging quality and interpretability (SUV distributions, background-to-target contrast)
- Practical imaging workflow parameters (time-to-scan, scan duration, feasibility)
What the FDA-cleared claim typically focuses on
Regulatory labeling for PSMA-PET tracers generally emphasizes imaging of PSMA-positive prostate cancer in specified clinical contexts. That framing matters for payer coverage policies that use indication language to define reimbursement eligibility.
What clinical trials of piflufolastat F-18 are ongoing, and what are their likely readouts?
A full “trial-by-trial” update requires a definitive list of currently active interventional studies and their posted status dates. Without a traceable trial registry snapshot in the supplied material, a complete, accurate status table cannot be produced.
High-probability trial categories that affect near-term adoption
Even without a full registry dump, clinical development activity for PSMA-PET tracers commonly clusters into:
- Prospective multicenter reader studies to support broader use and standardized interpretation
- Comparative studies against other PSMA radioligands (head-to-head imaging performance)
- Real-world evidence protocols linked to payer coverage and guideline alignment
- Radiation safety and workflow optimization studies at sites transitioning to new production or distribution models
What readouts matter to the market
Market impact comes when trials produce:
- Higher detection at low PSA thresholds versus comparators
- Better lesion characterization or reduced equivocal interpretations
- Evidence supporting clinical decision change and improved downstream management
What is the market size for PSMA PET imaging and where does piflufolastat F-18 fit?
PSMA PET is the leading adoption vector for molecular imaging in prostate cancer because it changes staging and management decisions. Piflufolastat F-18 is positioned as a PSMA ligand radiotracer that can be integrated into existing PET infrastructure, with the main gating factors being radiochemistry supply chains and reimbursement.
Market drivers
- Rising incidence of prostate cancer and growing use of PET for staging/restaging
- Guideline expansions for PSMA-PET in biochemical recurrence and metastatic workups
- Increasing radiopharmacy capacity and hub-and-spoke distribution models
- Payer acceptance expanding as evidence accumulates for clinical utility
Market constraints
- Radiotracer manufacturing logistics: short half-life, time-sensitive distribution
- Cyclotron and radiopharmacy throughput limits, impacting same-day availability
- Workforce and readout variability at smaller sites transitioning to PET interpretation
Competitive set (commercially relevant)
Piflufolastat F-18 competes against other PSMA-targeted PET ligands used for diagnostic imaging. Differentiation tends to be driven by:
- Imaging performance (lesion detectability, contrast)
- Practicality (time-to-injection, time-to-scan)
- Supply robustness (regional production coverage)
- Reimbursement and payer contracting history
How does Piflufolastat F-18 compare with competing PSMA PET tracers on adoption economics?
Competition is less about “clinical superiority in the abstract” and more about operational advantage and payer fit.
Adoption economics typically hinge on three variables
- Availability: same-day supply and geographic coverage
- Interpretability: consistent lesion detectability and lower ambiguity
- Reimbursement: coverage language aligned to labeling and evidence
What competitive claims usually move the market
- Trials showing improved detection at low PSA levels
- Evidence of concordance or reduced false negatives in clinically important settings
- Faster scan workflows enabling higher daily capacity at high-volume centers
When does piflufolastat F-18 lose exclusivity and what patent dates matter?
A credible exclusivity and patent calendar requires a confirmed Orange Book and patent publication dataset for piflufolastat F-18. Without a supplied Orange Book/patent list, an accurate expiration timeline cannot be constructed.
What to map for a PSMA PET tracer
For radiopharmaceuticals, key exclusivity and patent risk points often include:
- Drug substance/formulation composition patents (the labeled compound identity and variants)
- Radiolabeling and synthesis process patents (precursor chemistry, labeling steps, QC methods)
- Specific QA/QC release specifications and manufacturing methods
- Use or method-of-use patents (imaging workflows, patient selection criteria)
- Any exclusivity that is regulatory-pathway-linked (data exclusivity, marketing exclusivity) where applicable
What is the Orange Book status of piflufolastat F-18?
Orange Book status needs direct Orange Book listing verification. Without an input list of Orange Book entries and associated patents, status cannot be stated.
What “status” should be checked in practice
- Whether the product is listed as an FDA-approved drug with a patent list
- Which listed patents are tied to the active ingredient, dosage form, or method of use
- Patent expiry dates and pediatric extension indicators (if any)
- Whether any patents are “orphan” or otherwise extended
Can generic or biosimilar competitors enter piflufolastat F-18, and how does a Paragraph IV strategy translate for radiotracers?
For radiotracers, generic entry is typically constrained by:
- Control of the labeled molecule and its validated manufacturing process
- Production and release specifications
- PET-specific regulatory requirements and supply-chain realities
A Paragraph IV playbook depends on whether an ANDA-type pathway applies to this product and whether FDA has an eligible reference listed in a way that supports generic substitution. Without verified regulatory pathway details and listing structure, generic risk cannot be quantified.
Where competition is likely instead
In practice, the near-term competitive risk often comes from:
- Alternative PSMA PET ligands in clinical and reimbursement positioning
- Contracting and supply agreements with radiopharmacies and imaging networks
- Next-generation tracers with differentiated imaging performance or practical economics
What patent litigation affects piflufolastat F-18 and how strong is the patent estate?
Litigation risk depends on docketed disputes, listed patents, and enforcement history. Without provided litigation records or confirmed asserted patents, a defensible statement on litigation status and strength cannot be produced.
What matters in a tracer patent estate
- Scope of composition claims covering the labeled agent and close analogs
- Breadth of process claims covering radiolabeling synthesis, purification, and QC release
- Whether imaging use claims are directly enforceable under medical practice and reimbursement workflows
- International coverage patterns relevant to manufacturing and distribution
What market projections should investors and licensors use for the next 3–5 years?
A precise forecast requires baseline commercialization metrics (site adoption, order volumes, reimbursement trends) and verified clinical/program milestones. Without data in the prompt, a fully sourced numeric projection cannot be produced.
What drives the directionality of growth (framework)
Near-term growth generally follows:
- PSMA-PET utilization expansion in biochemical recurrence and decision-support pathways
- Increased PET capacity and radiopharmacy network build-out enabling more same-day availability
- Reimbursement expansion through payer policy updates and contractor adoption
What drives downside scenarios
- Supply interruptions or production capacity limitations at key manufacturing nodes
- Payer pushback limiting reimbursable indications
- Clinical substitution by alternative PSMA ligands with stronger trial differentiation or better economics
What commercial risks exist for piflufolastat F-18: supply, reimbursement, and payer contracting?
Supply risk
Short half-life radiotracers create operational exposure:
- Cyclotron availability and scheduling
- Radiolabeling time and release testing
- Transportation time windows and failure rates impacting daily inventory
Reimbursement risk
Coverage is the market valve for imaging tracers:
- Indication language alignment with payer medical policy
- Prior authorization requirements and coding discipline (where used)
- Evidence thresholds demanded by payers
Concentration risk
The economics of radiopharmaceutical contracts can concentrate demand:
- Imaging networks and oncology centers with multi-tracer purchasing influence
- Radiopharmacy service providers standardizing single-source purchasing
Key Takeaways
- Piflufolastat F-18 is a PSMA-targeted PET imaging radiotracer with commercial adoption tied to PSMA-PET workflow expansion in prostate cancer.
- Market growth is primarily constrained by radiotracer supply capacity and reimbursement coverage, not by clinical uncertainty alone.
- Patent and exclusivity timing, Orange Book status, and litigation impact cannot be stated without a verified listing and docket dataset.
- Competitive pressure is most likely from other PSMA PET ligands that win on practical imaging performance, supply coverage, and payer fit rather than rapid “generic” replacement.
FAQs
Is piflufolastat F-18 covered by Medicare or major commercial insurers for prostate cancer imaging?
Coverage depends on payer medical policy wording and indication language aligned to labeling and clinical utility evidence.
How does PSMA PET imaging change clinical management in biochemical recurrence?
It can shift staging and guide therapy selection by detecting disease outside conventional imaging sensitivity.
What manufacturing constraints limit same-day availability of PSMA PET tracers like piflufolastat F-18?
Radiolabeling yield, release testing time, transportation windows, and cyclotron scheduling capacity.
Do other PSMA PET tracers show better lesion detection at low PSA compared with piflufolastat F-18?
That depends on head-to-head trial design, reference standards, and reader methodology; adoption tends to follow evidence that reduces equivocal reads and improves low-PSA sensitivity.
What should imaging centers evaluate before switching PSMA PET radiotracers?
Availability reliability, interpretive consistency across readers, turnaround time, reimbursement contracting terms, and network-wide purchasing alignment.
References
- [No sources were provided in the prompt.]
